A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Subjects to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the CNS After Single-Dose Oral Administration
Latest Information Update: 17 Sep 2021
At a glance
- Drugs TAK 041 (Primary) ; Amphetamines
- Indications Cognition disorders; Schizophrenia
- Focus Pharmacodynamics
- Sponsors Neurocrine Biosciences
- 09 May 2018 Planned End Date changed from 23 Aug 2017 to 31 Oct 2019.
- 09 May 2018 Planned primary completion date changed from 23 Aug 2017 to 31 Oct 2019.
- 18 Dec 2017 Status changed from active, no longer recruiting to completed.